clocapramine

Clocapramine is an atypical antipsychotic of the imidobenzyl (also described as iminostilbene) class that was introduced in Japan in 1974 by Yoshitomi for the treatment of schizophrenia. It is primarily used to treat psychosis and has also been used as an adjunct to antidepressants for anxiety and panic disorders. Clocapramine acts mainly as an antagonist at dopamine D2 receptor, serotonin 5-HT2A receptor, alpha-1 adrenergic receptor, and alpha-2 adrenergic receptor; it also shows affinity for Sigma non-opioid intracellular receptor 1 (SIGMAR1). Its affinity for the 5-HT2A receptor exceeds that for D2 receptors, which contributes to its lower risk of extrapyramidal side effects compared to typical antipsychotics[1][2][3]. The drug does not inhibit reuptake of serotonin or norepinephrine[3]. It is administered orally.

Brand names

ClofektonPadrasen

Other names

clocapraminaclocapraminum